U.S. Dermatologics’ External Analgesic Patch Is Safe, Effective, Firm Says
This article was originally published in The Tan Sheet
U.S. Dermatologics' transdermal drug delivery platform is breathable and non-occlusive and should therefore be covered by the tentative final monograph for OTC external analgesics, the firm tells FDA in Sept. 30 comments
You may also be interested in...
FDA is proposing to clarify the tentative final monograph for OTC external analgesic drug products to exclude topical patch, plaster and poultice dosage forms, according to a Jan. 17 Federal Register notice
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning